HC Wainwright Issues Negative Forecast for ZNTL Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Investment analysts at HC Wainwright lowered their Q1 2025 EPS estimates for shares of Zentalis Pharmaceuticals in a research note issued on Thursday, March 27th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($0.52) per share for the quarter, down from their prior forecast of ($0.41). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Zentalis Pharmaceuticals’ Q2 2025 earnings at ($0.52) EPS, Q3 2025 earnings at ($0.53) EPS, Q4 2025 earnings at ($0.54) EPS, FY2025 earnings at ($2.11) EPS, FY2026 earnings at ($2.56) EPS, FY2027 earnings at ($2.61) EPS, FY2028 earnings at ($1.96) EPS and FY2029 earnings at ($0.99) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Wednesday, March 26th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.09. The company had revenue of $26.90 million for the quarter.

A number of other research firms have also weighed in on ZNTL. Wells Fargo & Company dropped their price target on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. Wedbush reaffirmed a “neutral” rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday. Finally, UBS Group decreased their price target on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $8.24.

Zentalis Pharmaceuticals Trading Up 1.1 %

Shares of NASDAQ:ZNTL opened at $1.81 on Monday. The stock has a 50 day moving average of $2.04 and a 200 day moving average of $2.85. The company has a market cap of $129.98 million, a PE ratio of -0.73 and a beta of 1.75. Zentalis Pharmaceuticals has a 12-month low of $1.61 and a 12-month high of $16.27.

Institutional Trading of Zentalis Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Voya Investment Management LLC grew its position in Zentalis Pharmaceuticals by 14.1% in the fourth quarter. Voya Investment Management LLC now owns 57,017 shares of the company’s stock worth $173,000 after acquiring an additional 7,058 shares in the last quarter. Wells Fargo & Company MN lifted its stake in shares of Zentalis Pharmaceuticals by 26.8% in the 4th quarter. Wells Fargo & Company MN now owns 34,609 shares of the company’s stock valued at $105,000 after purchasing an additional 7,305 shares during the last quarter. Erste Asset Management GmbH purchased a new position in shares of Zentalis Pharmaceuticals in the 3rd quarter worth approximately $37,000. Paloma Partners Management Co bought a new position in shares of Zentalis Pharmaceuticals during the 3rd quarter valued at approximately $37,000. Finally, Corton Capital Inc. purchased a new stake in Zentalis Pharmaceuticals during the 4th quarter valued at $32,000.

Insiders Place Their Bets

In other Zentalis Pharmaceuticals news, Director Jan Skvarka purchased 60,000 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Friday, January 31st. The shares were bought at an average price of $1.72 per share, for a total transaction of $103,200.00. Following the completion of the transaction, the director now owns 149,551 shares of the company’s stock, valued at approximately $257,227.72. This trade represents a 67.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Ingmar Bruns acquired 20,000 shares of the stock in a transaction on Thursday, February 6th. The shares were acquired at an average price of $2.28 per share, with a total value of $45,600.00. Following the transaction, the insider now directly owns 36,629 shares of the company’s stock, valued at $83,514.12. The trade was a 120.27 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 3.60% of the company’s stock.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.